Food and Drug Administration (HHS-FDA)
New funding opportunities and eligibility tips, weekly.
Weekly updates. Unsubscribe anytime. No spam.
This grant is designed to support innovative research and development of treatments for ultra-rare cancers, which are cancers affecting 300 to 400 people or less in the U.S. each year. The focus is on creating new methods and infrastructure to aid drug development, especially for pediatric and molecularly-defined subsets of more common cancers.
Who it's for: This grant is open to a wide range of applicants, including city or township governments, nonprofits, county governments, special district governments, state governments, independent school districts, private and public institutions of higher education, federally recognized Indian tribal governments, other Native American tribal organizations, individuals, and for-profit organizations.
Generated from official source details for readability
Eligible applicants include city or township governments, nonprofits with or without 501(c)(3) status, county governments, special district governments, state governments, independent school districts, private institutions of higher education, federally recognized Indian tribal governments, other Native American tribal organizations, public and state institutions of higher education, individuals, and for-profit organizations. This wide eligibility allows for diverse participation in the development of treatments for ultra-rare cancers.
This grant is open to a wide range of applicants, including city or township governments, nonprofits, county governments, special district governments, state governments, independent school districts, private and public institutions of higher education, federally recognized Indian tribal governments, other Native American tribal organizations, individuals, and for-profit organizations.
Funds can be used to develop infrastructure for data coordination, explore new clinical endpoints, support real-world data generation, identify new drug opportunities, and develop innovative delivery methods for therapies. The focus is on facilitating drug development for ultra-rare cancers.
Total Program Funding
$1,500,000
Expected Awards
3
Cost Sharing
Not Required
Award Range
N/A - $500,000
Deadline
Jun 15, 2026
Total Program Funding
$1,500,000
Always review the official grant listing for the most accurate and up-to-date information.
View Official Listing